Product news

Share this article:
The FDA has approved GlaxoSmithKline's Rotarix (rotavirus vaccine, live, oral) for the prevention of rotavirus gastroenteritis in infants. Rotarix is indicated to offer protection against the most commonly circulating rotavirus types in the US and allow infants to complete the vaccination series by four months of age. The US Centers for Disease Control and Prevention currently recommends that children complete the rotavirus immunization series by six months of age. 
 
Abbott said it has received marketing authorization from the European Commission for a new, lower-strength tablet formulation of HIV protease inhibitor, Kaletra (lopinavir/ritonavir).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters